ArticleInternational journal of women's health2025

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial.

Hao Su et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.